Novocure Ltd
NASDAQ:NVCR

Watchlist Manager
Novocure Ltd Logo
Novocure Ltd
NASDAQ:NVCR
Watchlist
Price: 30.97 USD 1.57% Market Closed
Market Cap: 3.4B USD
Have any thoughts about
Novocure Ltd?
Write Note

Net Margin
Novocure Ltd

-25.9%
Current
-24%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-25.9%
=
Net Income
-149.8m
/
Revenue
577.7m

Net Margin Across Competitors

Country JE
Market Cap 3.3B USD
Net Margin
-26%
Country US
Market Cap 199B USD
Net Margin
14%
Country US
Market Cap 191.3B USD
Net Margin
29%
Country US
Market Cap 141.3B USD
Net Margin
16%
Country US
Market Cap 134.2B USD
Net Margin
11%
Country IE
Market Cap 104.6B USD
Net Margin
13%
Country US
Market Cap 65.6B USD
Net Margin
9%
Country DE
Market Cap 58.1B EUR
Net Margin
8%
Country US
Market Cap 44.5B USD
Net Margin
74%
Country CN
Market Cap 307.8B CNY
Net Margin
33%
Country US
Market Cap 36.3B USD
Net Margin
9%
No Stocks Found

Novocure Ltd
Glance View

Market Cap
3.3B USD
Industry
Health Care

Novocure Ltd. operates in the intriguing intersection of medical innovation and patient-centric care, focusing on harnessing electric fields to treat cancerous tumors, a modality known as Tumor Treating Fields (TTFields). Founded in 2000 and based in the Isle of Jersey, the company has pioneered an unconventional approach that challenges traditional cancer treatments like chemotherapy and radiation. By deploying low-intensity, alternating electric fields through adhesive patches on the patient's body, TTFields interfere with the division of cancer cells, inhibiting tumor growth without the typical debilitating side effects. Novocure’s proprietary technology offers a unique, non-invasive treatment option primarily targeting aggressive cancers, such as glioblastoma and non-small cell lung cancer, positioning it as a notable innovator in the oncology space. The company's business model thrives on a blend of therapy innovation and strategic partnerships. Novocure generates revenue through sales of its wearable medical device, which continually delivers TTFields therapy. These sales are supplemented by the securing of insurance reimbursements, which is crucial for patient access and company profitability. By conducting numerous clinical trials, Novocure not only aims to expand the applicability of TTFields to other forms of cancer but also reinforces its value proposition to the healthcare community. Strategic collaborations with researchers and leading cancer centers further enhance its market penetration. As the company continues to invest in research and expand its treatment portfolio, its commitment to transforming cancer therapy by offering a new dimension of hope remains at the forefront of its mission.

NVCR Intrinsic Value
25.58 USD
Overvaluation 17%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-25.9%
=
Net Income
-149.8m
/
Revenue
577.7m
What is the Net Margin of Novocure Ltd?

Based on Novocure Ltd's most recent financial statements, the company has Net Margin of -25.9%.